OCULAR THERAPEUTIX, INC
No SEC Form 4 filings for $OCUL in the last 30 days.
Ocular Therapeutix (NASDAQ: OCUL) said it granted inducement equity awards to eight newly hired non-executive employees effective Aug. 3, 2026, under its 2019 Inducement Stock Incentive Plan and Nasdaq Listing Rule 5635(c)(4). The awards include non-statutory stock options for up to 53,975 shares at a $8.40 exercise price and RSUs for 17,450 shares, vesting over four and three years, respectively.
Ocular Therapeutix said its market research of retina specialists indicates about 80% would use AXPAXLI’s profile and over 90% would adopt it in the first year if approved. The investigational bioresorbable intravitreal hydrogel for wet AMD follows Phase 3 SOL-1 results versus aflibercept (p=0.0006). Ocular plans an NDA submission in Q4 2026.
The FBI reported July firearm background checks rose 9.3% to 2,194,563 versus July 2025, the second straight monthly increase. The article links checks to firearm demand and notes exposure for Smith & Wesson (SWBI) and Sturm Ruger (RGR). It also lists analyst rating/price-target updates for OCUL, RKLB, VELO, and ONDS, plus upcoming earnings expectations for several stocks.
Over the past 7 days, alphai's AI scored 6 news stories mentioning OCUL (OCULAR THERAPEUTIX, INC). Coverage has skewed bullish: 5 bullish, 1 neutral, and 0 bearish.
Recent OCUL coverage spans technology, earnings and regulation.
Routine inducement equity grants that can modestly dilute shares and add non-cash compensation expense, but they do not change near-term fundamentals or guidance.
Survey-based adoption expectations and Phase 3 SOL-1 efficacy details support a bullish pre-NDA narrative, but they are not revenue or prescription data.
Analyst target reiterations and the portfolio’s stated buying/option structure could support short-term sentiment for OCUL.
Beat on revenue and EPS, but flat sales and very weak adjusted operating margins keep the fundamental risk elevated.
The article frames a clearer regulatory path and potential review-time acceleration for AXPAXLI, alongside a cash-rich balance sheet.
alphai scores every news story that mentions OCUL with an AI model for sentiment and relevance, and aggregates insider trades from OCULAR THERAPEUTIX, INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Ocular Therapeutix (NASDAQ: OCUL) said it granted inducement equity awards to eight newly hired non-executive employees effective Aug. 3, 2026, under its 2019 Inducement Stock Incentive Plan and Nasdaq Listing Rule 5635(c)(4). The awards include non-statutory stock options for up to 53,975 shares at a $8.40 exercise price and RSUs for 17,450 shares, vesting over four and three years, respectively.
3 min readOcular Therapeutix said its market research of retina specialists indicates about 80% would use AXPAXLI’s profile and over 90% would adopt it in the first year if approved. The investigational bioresorbable intravitreal hydrogel for wet AMD follows Phase 3 SOL-1 results versus aflibercept (p=0.0006). Ocular plans an NDA submission in Q4 2026.
4 min readThe FBI reported July firearm background checks rose 9.3% to 2,194,563 versus July 2025, the second straight monthly increase. The article links checks to firearm demand and notes exposure for Smith & Wesson (SWBI) and Sturm Ruger (RGR). It also lists analyst rating/price-target updates for OCUL, RKLB, VELO, and ONDS, plus upcoming earnings expectations for several stocks.
9 min readOcular Therapeutix (NASDAQ:OCUL) reported Q2 CY2026 results. Revenue was $13.48 million, flat year over year, but 5.3% above Wall Street estimates. GAAP EPS was -$0.35, 11.2% better than consensus. The company said its June Investor Day outlined an FDA-aligned NDA submission path for AXPAXLI for wet AMD in Q4 2026. Shares rose 1.2% to $8.27.
5 min readOcular Therapeutix (OCUL) reported Q2 results for the period ended June 30: GAAP EPS of -$0.35 on revenue of $13.48M, both beating Wall Street expectations. The company said its AXPAXLI wet AMD NDA path is planned for Q4 2026 via FDA 505(b)(2), using SOL-1 data plus SOL-R interim safety. Cash was $598.6M.
7 min readOCULAR THERAPEUTIX, INC (OCUL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2621618d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights Ocular’s AXPAXLI TM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA
6 min readOcular Therapeutix (OCUL) told the H.C. Wainwright ophthalmology conference that the FDA has formally aligned on a complete submission package for AXPAXLI under a single-trial pathway for wet age-related macular degeneration. The company cited SOL-1 results, including a P value below 0.0006, and said it had $667 million cash at Q1 end.
6 min readOcular Therapeutix said it plans to submit an NDA for AXPAXLI in wet AMD in Q4 2026 after aligning with the FDA on a strategy based on SOL-1 efficacy/safety plus interim SOL-R safety data. The FDA will review the application using SOL-1 only; SOL-1 met its primary endpoint (p=0.0006). SOL-R was redesigned, with topline data expected in Q1 2028. The company also prioritized HELIOS-3 for diabetic retinopathy. Shares were up 6.49% to $9.52.
4 min readOCULAR THERAPEUTIX, INC (OCUL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001393434 0001393434 2026-06-10 2026-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readWaheed Nadia (Chief Medical Officer) sold 14,828 shares of OCULAR THERAPEUTIX, INC (OCUL) at $8.27 ($0.12M total) on 2026-06-03 under a Rule 10b5-1 trading plan.
2 min read
